Editas Medicine (EDIT) said late Thursday that it will focus on in vivo CRISPR-edited medicines and end the development of reni-cel to optimize cost structure and extend cash runway into Q2 2027.
The strategic transition will help the company accelerate in vivo human proof of concept in about two years, the company said.
Editas said it will also eliminate 65% of its workforce over the next six months. Chief Medical Officer Baisong Mei will leave the company, while Jessica Hopfield will become chair of the board on Dec. 31.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.